retatrutide eli lilly press release 2024 2025 Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial Eli Lilly's retatrutide sets new

The presence of GLP-1 in synovial fluid provides a biological basis for exploring its role in joint health

Tirzepatide, a dual GLP-1/GIP receptor agonist, introduces synergistic incretin signaling

Employers are increasingly prioritizing models that combine digital tools with licensed clinician support, ensuring care adapts as employee needs change

Molecules, 19 (11), 19066

Variants in FTO (fat-mass and obesity-associated), GLP1R (the GLP-1 receptor these compounds target), MC4R (satiety and energy balance), and TCF7L2 (glucose homeostasis) outline your baseline metabolic terrain

stimulates the work of the heart muscle